Nav interneta savienojuma — tiek rādīta saglabātā lapas versija.

Fortress Biotech…

USUSD
← Uz akciju filtru

Fortress Biotech Inc (US:FBIO) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 1. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.

Par uzņēmumu

Tīmekļvietne
fortressbiotech.com
Investoru attiecības
fortressbiotech.com/investors
Nozare
Health Care · Biotechnology: Pharmaceutical Preparations
Galvenā mītne
BAY HARBOR ISLANDS, United States
Izpilddirektors
Lindsay Allan Rosenwald
Darbinieki
34
Dibināts
2006
Apgrozībā esošās akcijas
33.35 milj.
Brīvā apgrozība
21.44 milj.
Tirgus kapitalizācija
73.37 milj. USD
Iekšējās personas
22.7%
Institucionālie investori
31.43%
Nozare (SIC)
Pharmaceutical Preparations
LEI
529900DZUWSYUURECK24
Izmaksas koeficients
0.4%
FCF
—
Parāds
35.0 milj. USD
neto nauda
Dividenžu stāžs
—
Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Biržas un tikeri

BiržaTikerisValūtaCenaVeids
US USA StocksFBIOUSD2.09 +2.45%parastās akcijas

Cena 3 mēnešu laikā

3M1Y3Y5Y
US:FBIO · USD
pieauguma diena krituma diena dividenžu ex-datums izmaksas datumsUzbrauciet / pieskarieties dienai — atvēršanas, slēgšanas, augstākā un zemākā cena

Dividendes

Dividenžu izmaksas netika atrastas (pārbaudīts 10.10.2026). Uzņēmums, visticamāk, nemaksā dividendes.

Ziņas šonedēļ

Pēdējās nedēļas laikā nav ziņu. Jaunākās ziņas: 08.09.2026.

reklāma

Lielākie akcionāri

TurētājsDaļaAkcijasPārskata datums
ROSENWALD LINDSAY A (Chi…≈13.74%4.59 milj.2026-03-18
WEISS MICHAEL S (Officer…≈6.82%2.28 milj.2026-03-18
JIN DAVID (Chief Financi…≈4.95%1.65 milj.2026-06-22
Vanguard Capital Managem…3.11%1.04 milj.2026-06-30
Opaleye Management Inc.2.67%890 0002026-06-30
VANGUARD INDEX FUNDS-Van…2.09%697 8022026-06-30
Mackenzie Financial Corp…1.67%555 6762026-06-30
GSA Capital Partners LLP1.37%458 4722026-06-30
Shikiar Asset Management…0.92%305 4692026-06-30
Geode Capital Management…0.9%300 5212026-06-30
VANGUARD INDEX FUNDS-Van…0.84%279 8912026-06-30
Blackrock Inc.0.67%224 7822026-06-30
Two Sigma Investments, L…0.64%213 7862026-06-30
LOBELL JONAH JAY (Direct…≈0.58%192 3972025-12-31
Bridgeway Capital Manage…0.53%177 3682026-06-30
Vanguard Fiduciary Trust…0.5%166 3712026-06-30
Bridgeway Funds, Inc.-Ul…0.46%152 3682026-06-30
HARVEY JIMMIE (Director)≈0.44%146 7042025-12-31
Fidelity Concord Street…0.43%143 1832026-07-31
KLEIN DOV (Director)≈0.39%130 1052025-12-31
HOENLEIN MALCOLM (Direct…≈0.35%115 7472025-12-31
LORENZ KEVIN R. (Directo…≈0.3%101 0092025-12-31
iShares Trust-iShares Mi…0.26%86 9832026-07-31
LU LUCY (Director)≈0.18%61 2732024-12-31
Fidelity Concord Street…0.15%49 3202026-07-31
Fidelity Concord Street…0.11%35 8742026-07-31
EA Series Trust-EA Bridg…0.07%25 0002026-06-30
Fidelity Concord Street…0.06%18 5502026-07-31
VANGUARD Inst. INDEX Fd.…0.05%18 0512026-06-30